KAT2B and neoplasm: At present, most studies tend to support the tumor suppressive effect of KAT2B, which is downregulated in esophageal squamous cell carcinoma (ESCC) and intestinal-type gastric cancer compared to adjacent non-tumor tissues (Zhu et al., 2009; Ying et al., 2010).